Lambert-Eaton myasthenic syndrome
Neurology · 2021–2022
2decisions
1medicine
1carried consumer input
9individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| amifampridine Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above. | Mar 2022 | Recommended with restriction | 9 individuals |
| amifampridine Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above. LEMS is a rare neuromuscular disorder characterized by… | Nov 2021 | Not recommended | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.